Patent SG-11201809316X-A (SG)
Title: Bispecific antibodies targeting egfr and her2
Inventor: ZHUKOVSKY EUGENE
IPC: C07K16/46
Filed: 2017-04-28
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1#11101111 0 11101 HOE 010 1111 1 0 I 31101110111111100110111101111011# Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" 1 WO 2017/186950 Al 02 November 2017 (02.11.2017) WIP0 I PCT (51) International Patent Classification: Rue des Apothicaires Parc Euromedecine, 34298 MONT- C07K16/28 (2006.01) C07K 16/46 (2006.01) PELLIER CEDEX 5 (FR). (21) International Application Number: (72) Inventors: ZHUKOVSKY, Eugene; 5 avenue Fremiet, PCT/EP2017/060280 75016 Paris (FR). LEGER, Olivier; 603 Route des Luches, (22) International Filing Date: 74800 Saint Sixt (FR). GERARD, Pierre-Emmanuel; 113 28 April 2017 (28.04.2017) rue de la Tour, 75116 Paris (FR). PELEGRIN, Andre; INSERM-Transfert 7 me Watt, Paris Biopark, 75013 Paris (25) Filing Language: English (FR). LARBOURET, Christel; INSERM-Transfert 7 rue (26) Publication Language: English Watt, Paris Biopark, 75013 Paris (FR). (30) Priority Data: (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue 16305496.8 28 April 2016 (28.04.2016) EP Louis le Grand, 75002 PARIS (FR). (71) Applicants: BIOMUNEX PHARMACEUTICALS (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, [FR/FR]; 113 me de la Tour, 75116 PARIS (FR). INSERM AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (INSTITUT NATIONAL DE LA SANTE ET DE LA CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, RECHERCHE MEDICALE) [FR/FR]; 101 rue de Tol- DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, bias, 75013 PARIS (FR). UNIVERSITE DE MONT- HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, PELLIER [FR/FR]; 163 me Auguste Broussonnet, 34090 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MONTPELLIER (FR). INSTITUT REGIONAL DU MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, CANCER DE MONTPELLIER (ICM) [FR/FR]; 208, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, = = (54) Title: BISPECIFIC ANTIBODIES TARGETING EGFR AND = = = = _ = AA = = = = I = _ = _ — cc = 4111 : set ot Il © kr) FIGURE c:r c)1: 1-1 (57) : The present disclosure relates to bispecific antibodies ---- these antibodies. The bispecific antibodies consist of one complete IN to each NH terminal region of both VH chains of the antibody. The © of the heavy chain (VH) and the light chain (VL) variable regions of f'1 cetuximab and trastuzumab, respectively HER2 S Native. 1.Pwative 1 two niwiallor targeting antibody bispecific . Ni BB N ative intrAuced in C a .1.1 EGFR and HER2, on which two VH- antibodies constructed monoclonal antibodies targeting Positive alt -Negative VL 1 and methods for the production of chains are attached via a linker use the amino acid sequences EGFR and HER2, namely C [Continued on next page] WO 2017/186950 Al MIDEDIMOMOIDEIROIDEMOMMEIRIBINHOMEMOIS SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))